These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
80 related articles for article (PubMed ID: 11267025)
1. Preventing anti-Gal response in xenograft recipients by an alpha-Gal toxin. Tanemura M; Yin D; DiSesa VJ; Galili U Transplant Proc; 2001; 33(1-2):699-700. PubMed ID: 11267025 [No Abstract] [Full Text] [Related]
2. Elimination of anti-Gal B cells by alpha-Gal ricin1. Tanemura M; Ogawa H; Yin DP; Chen ZC; DiSesa VJ; Galili U Transplantation; 2002 Jun; 73(12):1859-68. PubMed ID: 12131678 [TBL] [Abstract][Full Text] [Related]
3. In Contrast to Anti-C5 Therapy, Cobra Venom Factor Does Not Prevent Rejection of Xenogeneic Cartilage in Mice. Brokaw JL; Costa C Transplant Proc; 2015 Oct; 47(8):2397-9. PubMed ID: 26518939 [TBL] [Abstract][Full Text] [Related]
4. Pig kidney transplantation in baboons: anti-Gal(alpha)1-3Gal IgM alone is associated with acute humoral xenograft rejection and disseminated intravascular coagulation. Bühler L; Yamada K; Kitamura H; Alwayn IP; Basker M; Appel JZ; Colvin RB; White-Scharf ME; Sachs DH; Robson SC; Awwad M; Cooper DK Transplantation; 2001 Dec; 72(11):1743-52. PubMed ID: 11740383 [TBL] [Abstract][Full Text] [Related]
6. Anti-Gal antibody-mediated allograft rejection in alpha1,3-galactosyltransferase gene knockout mice: a model of delayed xenograft rejection. Pearse MJ; Witort E; Mottram P; Han W; Murray-Segal L; Romanella M; Salvaris E; Shinkel TA; Goodman DJ; d'Apice AJ Transplantation; 1998 Sep; 66(6):748-54. PubMed ID: 9771838 [TBL] [Abstract][Full Text] [Related]
7. The in vitro and in vivo effects of anti-galactose antibodies on endothelial cell activation and xenograft rejection. Xu H; Yin D; Naziruddin B; Chen L; Stark A; Wei Y; Lei Y; Shen J; Logan JS; Byrne GW; Chong AS J Immunol; 2003 Feb; 170(3):1531-9. PubMed ID: 12538718 [TBL] [Abstract][Full Text] [Related]
8. Lewis rat pancreas, but not cardiac xenografts, are resistant to anti-gal antibody mediated hyperacute rejection. Yin DP; Sankary HN; Ma LL; Shen J; Qin Y; Blinder L; Williams JW; Chong AS Transplantation; 2001 May; 71(10):1385-9. PubMed ID: 11391223 [TBL] [Abstract][Full Text] [Related]
9. A murine model of antibody-mediated hyperacute rejection by galactose-alpha(1,3)galactose antibodies in Gal o/o mice. McKenzie IF; Li YQ; Patton K; Thall AD; Sandrin MS Transplantation; 1998 Sep; 66(6):754-63. PubMed ID: 9771839 [TBL] [Abstract][Full Text] [Related]
10. Development and characterization of anti-Gal B cell receptor transgenic Gal-/- mice. Xu H; Sharma A; Lei Y; Okabe J; Wan H; Chong AS; Logan JS; Byrne GW Transplantation; 2002 May; 73(10):1549-57. PubMed ID: 12042639 [TBL] [Abstract][Full Text] [Related]
11. Intact active bone transplantation synergizes with anti-CD40 ligand therapy to induce B cell tolerance. Yin D; Ma L; Varghese A; Shen J; Chong AS J Immunol; 2002 May; 168(10):5352-8. PubMed ID: 11994494 [TBL] [Abstract][Full Text] [Related]
12. Evidence that tilapia islets do not express alpha-(1,3)gal: implications for islet xenotransplantation. Leventhal JR; Sun J; Zhang J; Galili U; Chong A; Baker M; Kaufman DB; Wright JR Xenotransplantation; 2004 May; 11(3):276-83. PubMed ID: 15099208 [TBL] [Abstract][Full Text] [Related]